Drug Discovery Market Size to Rise USD 160.31 Billion by 2034
Ottawa, April 14, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global drug discovery market size was evaluated at USD 65.88 billion in 2024 and is predicted to grow around USD 160.31 billion by 2034, expanding at a CAGR of 9.3% during the forecast period 2025 to 2034. The drug discovery market growth is driven by collaborative advancements, open innovation, a shift toward precision or personalized medicine, increased availability of omics data, integration of machine learning (ML) and artificial intelligence (AI), and increasing R&D investment from pharmaceutical and biotechnology companies.
Request a Sample Databook to Explore our Insights - https://www.statifacts.com/stats/databook-download/7737
Industry SnapshotDrug discovery is the process of identifying and characterizing molecules with the capacity to safely modulate disease, to bring medicines that can enhance patients' lives. It is a lengthy and resource-intensive method to requires close cooperation across many disciplines. Drug discovery is essential for treating illness or disease for which no other treatment exists, or it provides additional benefits over the prevailing treatments, like fewer drug-drug interactions, enhanced amenability, higher therapeutic efficacy, and less adverse effects.
The drug discovery market refers to the production, distribution, and use of drug discovery, which is a research process that identifies and develops a molecule that produces a desired effect in a living organism. Preclinical drug discovery aims to deliver one or more clinical candidate molecules, each of which has sufficient evidence of biological activity at a target related to disease and also sufficient safety and drug-like properties so that it can be entered into human testing.
Advancements in the drug discovery process are undergoing a profound transformation, with novel technologies like organoids, nanotechnology, AI, and organs-on-a-chip models playing an important role. In March 2025, a new AI tool for drug discovery, TxGemma launched by Google. It helps to enhance the efficiency of AI-based drug discovery.
Drug Discovery Market Key Highlights
North America led the global market with the highest market share in 2024.
Asia Pacific is predicted to grow at the fastest rate in the market during the forecast period.
By drug type, the small molecule segment held the largest market share in 2024.
By drug type, the large molecule segment is predicted to experience rapid growth in the upcoming years.
By end-user, the pharmaceutical companies segment is estimated to hold the highest market share in 2024.
By end-user, the CRO segment is projected to grow substantially during the forecast period.
Major Key Trends in the Drug Discovery Market:
Stringent regulatory guidelines: The benefits of stringent regulatory guidelines include increased profitability, reduced risk, improved branding, fostering healthy competition, enhanced safety and efficiency in the workplace, and avoidance of unnecessary legal issues.
Increasing adoption of single-use technologies: With single-use technologies, validation, cleaning, and sterilization between production runs are reduced. This significantly reduces changeover times, making operations more efficient and faster.
Innovation in bioprocessing technology: In the bioprocess workflow, many key stages are transformed by the single-use technologies. These advancements reduce contamination risks, provide versatility, and improve cost efficiency.
Order the Premium Databook Today at the Discounted Rate of $1550! https://www.statifacts.com/order-databook/7737
Limitations & Challenges in the Drug Discovery Market:
High initial investment costs: Drug discovery is a lengthy and expensive process. The use of innovative drug discovery informatics tools like hardware, software, and training, which needs a high investment cost.
Data security and privacy concerns: Data privacy risks include phishing scams, online tracking, data breaches, identity theft, and social engineering attacks. Data security risks also include failure to access control, implement data encryption, and secure data storage practices that may expose sensitive data to theft.
Development of Drug Discovery Platforms: Market's Largest PotentialWith sophisticated data modeling, companies can run through 'AI-based drug discovery platforms' to determine novel medical uses. Artificial intelligence (AI) has the potential to revolutionize the drug discovery process, offering enhanced speed, accuracy, and efficiency. The benefits of AI in drug discovery include that it plays an important role in safety prediction, it can swiftly analyze high datasets of chemical compounds and their interrelationships with biological targets, it is highly compatible with personalized medicine, it targets rare diseases, cost savings and a rapid drug discovery process.
In March 2025, the launch of a new end-to-end technology platform was announced by Boehringer Ingelheim, and the platform was designed to streamline data and processes, allowing more efficient and faster drug development.
Regional Analysis:
North America Held the Dominant Position: Technological Advancement to Support Growth
North America held the largest share of the drug discovery market in 2024. New Drug Development American consumers have the advantage of having access to the most advanced and safest innovative pharmaceutical system in the world. The U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical advantages, which drives the growth of the market in the region.
Major Factors for the Market's Expansion in North America
In July 2023, the acquisition of one of North America's largest discovery Contract Research Organizations (CROs), Canada-based NuChem Sciences, was announced by leading integrated drug discovery partner Sygnature Discovery.
In July 2024, for drug discovery, McGill, industry, CQDM, and Brain Canada collaborated.
What Expect from Asian Countries till 2034?Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Countries in the Asia Pacific region, including Japan, South Korea, Singapore, Taiwan, and China, have become key players in AI-based drug discovery because of substantial spending in research, efforts to attract top talent, and strong academic institutions driving the growth of the drug discovery market.
India: India offers many benefits for clinical research, such as a high patient population not exposed to treatment, world-class health services with well-trained doctors, and has appeared as a strong base for clinical trials.
In February 2025, public access to the cancer genome database to help cancer research and drug discovery in India was launched by IIT Madras.
Japan: Japan's drug laws are very strict. The Pharmaceuticals and Medical Devices Agency (PDMA) is the regulatory agency that reviews the efficacy, quality, and safety of medical products to be marketed in Japan from a scientific aspect.
In September 2024, for the master service agreement for drug discovery projects, Axcelead Drug Discovery Partners, Inc. (Axcelead DDP, HQ. Fujisawa, Kanagawa, Japan) collaborated with Academia Pharmaceuticals, Inc. (HQ. San Diego, CA, USA).
Drug Discovery Market Scope
Report Attribute
Key Statistics
Market Size in 2025
USD 72.01 Billion
Market Size by 2034
USD 160.31 Billion
Growth Rate from 2025 to 2034
CAGR of 9.3%
Base Year
2024
Forecast Period
2025 to 2034
Segments Covered
By Drug Type, By End User, By Technology, and By Region
Regions Covered
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Drug Type InsightsThe small molecule segment maintained a leading position in the drug discovery market in 2024. Small molecule drugs offer many benefits, starting with their high oral bioavailability, which enables convenient self-administration, most of them in oral solid dose (OSD) form. This advances patient compliance, making them suitable for the long-term treatment of chronic diseases.
In April 2025, the AI Small Molecule Drug Discovery Center, which was created to integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented precision and speed, was launched by The Icahn School of Medicine at Mount Sinai.
The large molecule segment is set to experience the fastest rate of market growth from 2025 to 2034. Large molecules are also known as biologics, which are derived from living organisms and are inherently critical to develop and manufacture. As compared to small-molecule chemical API, biological drugs mostly end up in a parenteral drug product rather than in an oral dose.
In October 2024, to advance small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, Accenture collaborated with 1910 Genetics, a biotechnology company.
End-user InsightsThe pharmaceutical companies segment dominated the drug discovery market. The pharmaceutical companies sector deals with the development, discovery, production, and marketing of drugs licensed for use as medicine. It operates under strict regulations to ensure the safety and effectiveness of drugs. Pharmaceutical companies are responsible for the continuous delivery of life-saving medicines to patients. Pharmaceutical companies conduct continuous testing to ensure that medicines meet quality standards before they are exported to the market.The CRO segment is projected to expand rapidly in the drug discovery market in the coming years. CROs provide critical information about the safety and effectiveness of the new drugs and play an important role in ensuring drugs are safe for use by patients. CRO also provides access to specialized expertise and scalability in conducting trials. CRO can offer cost savings for sponsors by eliminating the time it takes to conduct a trial compared to a sponsor doing so in-house.
Browse More Research Reports:
The global drug and gene delivery systems market size accounted for USD 727.45 million in 2024 and is expected to exceed around USD 1,754 million by 2034, growing at a CAGR of 9.2% from 2025 to 2034.
The U.S. cancer immunotherapy drug discovery outsourcing market size accounted for USD 400.10 million in 2024 and is expected to exceed around USD 1,037.76 million by 2034, growing at a CAGR of 10% from 2025 to 2034.
The U.S. drug discovery market size is calculated at USD 25.20 billion in 2024 and is predicted to reach around USD 60.21 billion by 2034, expanding at a CAGR of 9.1% from 2025 to 2034.
The U.S. genomics market size was estimated at USD 13.85 billion in 2024 and is projected to hit around USD 67.15 billion by 2034, growing at a CAGR of 17.1% during the forecast period from 2025 to 2034.
The global eDiscovery market size is calculated at USD 13,141 million in 2024 and is predicted to attain around USD 29,439 million by 2034, expanding at a CAGR of 8.4% from 2025 to 2034.
The global antibody discovery market size is calculated at USD 8,700 million in 2024 and is predicted to reach around USD 22,570 million by 2034, expanding at a CAGR of 10% from 2025 to 2034.
The global cloud-based drug discovery platform market size is predicted to gain around USD 8,029 million by 2034 from USD 2,429 million in 2024 with a CAGR of 12.7% 2025 to 2034.
Order the Premium Databook Today at the Discounted Rate of $1550! https://www.statifacts.com/order-databook/7737
Drug Discovery Market Top Companies:
Pfizer Inc.
GlaxoSmithKline PLC
Merck & Co. Inc.
Agilent Technologies Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Bayer AG
Abbott Laboratories Inc.
AstraZeneca PLC
Shimadzu Corp
Recent Breakthroughs in the Global Drug Discovery Market:
In March 2025, TxGemma, an open collection of AI models designed to improve the efficiency of clinical trial and drug discovery predictions, was launched by Google DeepMind.
In January 2025, Manas AI with $26.4M for AI drug discovery was launched by LinkedIn Cofounder. The company, in collaboration with Microsoft, goal to develop cancer medicines with treatments for rare conditions and autoimmune diseases.
Segments Covered in the Report
By Drug Type
Small Molecule
Large Molecule
By End User
Pharmaceutical Companies
CROs
Others
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Other Technologies
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
You can place an order or ask any questions, please feel free to contact us at sales@statifacts.com
Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here - https://www.statifacts.com/get-a-subscription
Contact US
Ballindamm 22, 20095 Hamburg, Germany
Web: https://www.statifacts.com/
Europe: +44 7383 092 044
About US
Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG.
Our Trusted Data Partners:Precedence Research | Towards Healthcare | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Nova One Advisor
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Bitcoin price hits record high above $123,500 amid crypto rally
Bitcoin (BTC-USD) surged to a new all-time high above $123,500 (£90,984) in early Thursday trading, extending a week-long rally that has lifted the broader cryptocurrency market. Bitcoin briefly traded at $123,512 before easing back to around $121,700. The world's biggest cryptocurrency is now up more than 6% over the past week, breaking through its previous July peak of just over $120,000. Read more: Crypto live prices 'Bitcoin's latest rally reflects the blurring lines between crypto and traditional assets, happening faster than institutional adoption timelines predicted,' VOOI CEO and co-founder Will K said. 'While ETFs brought institutions into bitcoin, retail traders are returning to evolved decentralised platforms that have shed their clunky origins.' Ethereum (ETH-USD) outpaced bitcoin in percentage gains, jumping 28% over the past seven days to trade above $4,742, inching closer to its November 2021 record of $4,865. 'Ethereum's rally is being driven by strong ETF inflows, institutional accumulation, and a favourable macro backdrop after softer CPI data boosted rate-cut expectations,' Bitfinex head of derivatives Jag Kooner said. 'Traders have rotated back into risk, with bitcoin and ether both seeing renewed long positioning, while options data shows low implied volatility and a build-up in open interest, signalling that markets expect a sharp move ahead but are hedging downside risk.' The total cryptocurrency market capitalisation now stands at $4.23tn, up 1.9% on Thursday, according to CoinMarketCap data. The crypto rally comes as US equities closed higher on Wednesday, with the S&P 500 (^GSPC) and Nasdaq (^IXIC) hitting fresh record highs this week. The broader risk-on sentiment has spilled over into digital assets. Read more: One US law reshaped crypto overnight. Ripple explains why Bitcoin's surge has been underpinned by a friendlier regulatory climate in Washington. Earlier this month, US president Donald Trump signed an executive order directing federal banking regulators to scrap 'reputational risk' as a factor in supervision, a designation that had often led banks to cut ties with lawful crypto firms. The move, part of a broader rollback of restrictions critics dubbed 'Operation Choke Point 2.0,' has been coupled with the disbanding of the Justice Department's National Crypto Enforcement Team and new legislation to establish a federal framework for stablecoins. Industry leaders have said the shift is clearing a path for greater institutional participation in digital assets, adding momentum to bitcoin's rally. Read more: Why pension funds are buying bitcoin What is a spot bitcoin ETF and why has it sparked a crypto rally? How AI could change the internet
Yahoo
3 hours ago
- Yahoo
Kuros Biosciences Reports First Half of 2025 Results
Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million) The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024 Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%). After amortization, depreciation, the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million) Cash position remains strong while funding strategic growth initiatives and investing in working capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group's primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. Revenue from Direct MagnetOs product sales increased 77% year-on-year to USD 62.7 million (H1 2024: USD 35.4 million). The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an operating loss of USD (0.2) million in H1 2024. The Group achieved an EBITDA of USD 5.1 million in H1 2025, increasing from USD 0.8 million in H1 2024. Adjusted EBITDA* totaled at USD 7.8 million, up from USD 4.5 million in H1 2024. This represents an adjusted EBITDA* margin of 12.3%. The Group does not expect a material impact from U.S. tariffs in 2025. Finally, the reporting currency was changed from Swiss francs (CHF) to U.S. dollars (USD) to reflect the Group's primary market and business activities. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.' Commercial, Operational & Regulatory Highlights Medtronic U.S. Spine Partnership Gains Traction – In January 2025, Kuros finalized a five-year exclusive strategic sales agent agreement with the Medtronic spinal division for MagnetOs in mutually agreed upon U.S. sales territories. The partnership, which evolved from a successful pilot, is accelerating commercial access and hospital entry across key geographies, serving as a major force multiplier for Kuros' U.S. growth. FDA Clearance & First Cases with MagnetOs MIS Delivery System – Kuros has received FDA 510(k) clearance for its MagnetOs MIS Delivery System, a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. The system enables three times faster graft placement compared to traditional funnel-based methods, combining precise delivery with compelling Level I clinical data.1,2 Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. 'MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate delivery and efficiency. It pairs streamlined handling with compelling clinical data, making it a meaningful advancement for surgeons who value both efficiency and biologically robust healing,' said Dr. Park. Continued Momentum in Extremities Market – With an established team dedicated to the extremities segment, Kuros is laying the groundwork for long-term success. Early progress has been promising, and the team continues to focus on targeted surgeon and distributor engagement, training, and brand awareness through an omnichannel strategy that includes key scientific meetings and driving social media presence. Global Expansion Accelerates – Following recent approval of MagnetOs Granules, ANVISA has now approved MagnetOs Putty for use in Brazil, further expanding Kuros' commercial presence in the growing South American spine market and building on recent global clearances in Lebanon and beyond. First Capital Markets Day Successfully Completed – In May 2025, Kuros hosted its inaugural Capital Markets Day in Zurich, welcoming over 130 attendees in-person and online. The event showcased the company's scientific leadership, global commercial strategy, and clinically proven differentiated approach to bone healing – featuring insights from a leading U.S. foot and ankle surgeon on how bone graft choice directly impacts patient outcomes and day-to-day quality of life. In addition, the Group presented the progress made in transforming its business from a functional, structural and digital perspective. New U.S. Headquarters and Production Facility Construction Underway – As part of its U.S. operational expansion strategy, Kuros has secured a location in Atlanta for a new office and manufacturing facility. The site is expected to support diversified manufacturing and enable Kuros to scale operations and engagement in line with accelerating demand for MagnetOs, with an immersive experience for surgeons, partners, and investors—highlighting the science, innovation, and clinical impact of MagnetOs in an engaging environment. Net operating costs Cost of goods sold amounted to USD 7.1 million in H1 2025 (H1 2024: USD 3.9 million) of which USD 0.9 million (H1 2024: USD 0.9 million) relate to the amortization of capitalized R&D. Net operating costs from continuing operations amounted to USD 52.8 million in H1 2025, compared to USD 32.0 million in the prior year period. Sales and marketing costs increased from USD 20.7 million in H1 2024 to USD 37.4 million in H1 2025, primarily driven by an expanded sales force and higher sales and distribution expenses, in line with the Group's continued commercial expansion. The increase also reflects the initial investments to penetrate the extremities and international markets, supporting future revenue growth and a broader market reach. Research and development costs of continuing operations increased from USD 3.6 million in H1 2024 to USD 4.3 million in H1 2025. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount, reflecting the Group's ongoing commitment to innovation to support long-term growth. General and administrative costs increased from USD 7.8 million in H1 2024 to USD 11.1 million in H1 2025. The increase was mainly driven by the scaling up of back-office functions and building the digital infrastructure to support business growth. Operating profit/ (loss) and group net result The operating profit from continuing operations amounted to USD 3.5 million (H1 2024: operating loss from continuing operations of USD (0.2) million). After accounting for the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million). Financial position and other assets Cash and cash equivalents amounted to USD 18.4 million as of H1 2025 (December 31, 2024: USD 19.8 million). The decrease in cash balance compared to year-end 2024 is mainly attributable to ongoing investments in growth initiatives and working capital to support rising demand. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to USD 45.3 million as of H1 2025. This is an increase of USD 7.8 million from USD 37.5 million as of December 31, 2024. As of H1 2025, total intangible assets amounted to USD 17.6 million (2024: USD 16.4 million) and goodwill amounted to USD 24.2 million (2024: USD 21.3 million). Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company remains sufficiently financed to support its planned organic growth path and continues to expect robust sales growth of at least 60% in 2025. Based on the solid performance in the first half of the year, Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures H1 2025 H1 2024Restated In TUSD, IFRS Revenue from product sales 63,480 35,684 Cost of goods sold (7,148) (3,896) Gross profit 56,332 31,788 Sales and marketing costs (37,394) (20,723) Research and development costs (4,305) (3,610) General and administrative costs (11,136) (7,826) Other income 6 126 Net operating costs (52,829) (32,033) Operating profit/ (loss) 3,503 (245) Net finance result (3,366) 1,857 Profit before tax 137 1,612 Income taxes (2,173) (1,466) Net (loss)/ profit from continuing operations (2,036) 146 Profit/ (loss) from discontinued operation, net of tax 23 (382) Net loss (2,013) (236) Net loss per share from continuing operations (in USD) (0.05) 0.00 Net loss per share (in USD) (0.05) (0.01) June 30, 2025 Dec 31, 2024Restated Cash and cash equivalents 18,442 19,762 Trade and other receivables 26,886 17,698 Half Year Report 2025The Kuros Biosciences Half Year Report 2025 can be downloaded via the following link on our website: Kuros Biosciences Interim Report 2025 Half Year Results 2025 – WebcastKuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast RegistrationThe respective presentation can be downloaded via the following link:Kuros Biosciences WebCast H1 2025 Upcoming EventsOctober 16, 2025 – Trading Update Q3 2025 For further information, please contact:Kuros Biosciences AG Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ Growing bone with MagnetOsTM gives surgeons confidence where it matters most – delivering predictable fusion outcomes.2 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs).2 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.**†2,3 MagnetOs grows bone on its own thanks to NeedleGripTM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.‡§4-9 Ready-to-use, easy to mold, and reliably staying put10, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶6-9 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Adjusted EBITDA excludes recurring and one-time share-based compensation and the relevant social security charges** 19 of initial 100 patients were active smokers.† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit § MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space. Data on file. MagnetOs MIS. Stempels, et al. Spine. 2024;49(19):1323-1331. van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. van Dijk, et al. eCM. 2021;41:756-73. van Dijk, et al. J Immunol Regen Med. 2023;19:100070. Instructions for Use (IFU) MagnetOs Granules. Instructions for Use (IFU) MagnetOs Putty. Instructions for Use (IFU) MagnetOs Easypack Putty. Instructions for Use (IFU) MagnetOs Flex Matrix. Data on file. MagnetOs Putty and MagnetOs Easypack Putty. Attachment Kuros Biosciences Press Release H1 2025 Results
Yahoo
6 hours ago
- Yahoo
Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather
By Jaspreet Kalra SINGAPORE (Reuters) -The U.S. dollar was under pressure on Thursday as traders piled into wagers that the Federal Reserve will resume cutting interest rates next month, powering Bitcoin to a record high, while a blistering rally in regional stocks took a breather. MSCI's gauge of equities in Asia excluding Japan nudged higher and lingered near its loftiest level since September 2021, taking cues from Wall Street, where the S&P 500 and Nasdaq indexes hit new closing highs for the second straight day. The MSCI All Country World Index rose to a record high for the second straight session on Wednesday. Japan's Nikkei fell after a searing six-day rally that boosted it past the 43,000 mark for the first time. Shares in Korea and Taiwan were slightly lower as well. China's blue-chip stock index and shares in Hong Kong gained. The dollar fell to a two-week low against a basket of major peers on shifting expectations of U.S. rate cuts, with comments from the U.S. Treasury Secretary also helping bolster expectations of an outsized 50 basis point cut. The Japanese yen hit a three-week high of 146.38 per dollar in early trading. [FRX/] Treasury Secretary Scott Bessent said on Wednesday that an aggressive half-point cut was possible in September after revised labour market data from last week showed that job growth had slowed sharply in May, June and July. Goldman Sachs said on Wednesday in a research note it expects the U.S. Federal Reserve to deliver three 25-basis-point interest rate cuts this year and two more in 2026. Traders are pricing in certainty of a rate cut in September with odds of a 50 bps cut rising to 7%, up from 0% a week earlier. While a tame U.S. inflation report this week boosted the case for rate cuts, some analysts have cautioned against market complacency, saying that upcoming data may alter expectations. "We're not as convinced of a 25bp FOMC rate cut in September as financial markets, let alone a 50bp rate cut," said Carol Kong, economist and currency strategist at Commonwealth Bank of Australia. "There will be another CPI and payrolls report ahead of the September meeting that can make or break the case for a rate cut," Kong said. BITCOIN, GOLD Optimism on monetary policy easing in the world's largest economy also powered cryptocurrency bitcoin to an all-time high of $124,002.49 with analysts also pointing to recent financial sector reforms as a tailwind for the asset class. Bitcoin has risen 32% so far in 2025, and the second largest cryptocurrency, Ethereum, has climbed 41% and is hovering just shy of its all-time high hit in November 2021. In commodity markets, gold prices rose 0.5% to $3,371 and crude oil prices edged up after hitting a two-month low on Wednesday as investors kept their focus on the summit between U.S. President Donald Trump and Russian leader Vladimir Putin on Friday. [O/R] [GOL/] Trump on Wednesday threatened "severe consequences" if Putin did not agree to peace in Ukraine but also said that a meeting between them could swiftly be followed by a second one that would include Ukrainian President Volodymyr Zelenskiy. In the past, Trump has said both sides will have to swap land to end fighting that has cost tens of thousands of lives and displaced millions. "While lack of progress towards a ceasefire may lead to renewed threats of secondary oil tariffs/sanctions, we see limited risk of large disruptions in Russia supply," analysts at Goldman Sachs wrote in a note. Large volumes of Russian exports, the possibility of deepening price discounts to maintain demand, and the likely eagerness of key buyers India, and especially China, to continue energy cooperation with Russia are expected to avert major disruptions, they said. Trump signed an executive order last week levying an additional 25% tariff on India's exports to the U.S., saying that the country directly or indirectly imported Russian oil. He has also hinted at similar tariffs on China.
